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The etiology of many human diseases is complex and often
involves a combination of genetic and environmental risk factors.
Genetic risk factors can be common polymorphisms that are
neither necessary nor sufficient to develop the disease. The aims
of genetic analyses are to (1) identify the genetic factors and (2)
model their role, and the interactions between them and with
environmental factors.
Different strategies have been developed that take advantage of
the information provided by genetic markers in families of
affected individuals. A genetic marker is a polymorphic locus, that
is, it has multiple allelic forms segregating in a Mendelian manner.
Thanks to molecular technology, the number of highly polymor-
phic genetic markers increases very rapidly and provides land-
marks to the whole genome. A possible strategy to detect the
presence of a risk factor in a region of the genome is to
systematically search for linkage with random genetic markers.
SYSTEMATIC SCREENING OF THE GENOME BY THE
LINKAGE TEST
Linkage between a genetic marker and a disease means that
there is nonindependence in the disease and marker transmission
in families. It implies a familial correlation between the disease
status and the marker genotypes.
Different statistics may then be used for testing linkage. For a
long time, the most widely applied method was the lod score
method, proposed by Morton [1]. In normal conditions, when the
disease is monogenic with well-specified genetic parameters (dis-
ease allele frequency, dominance relationship between normal
and disease alleles, penetrance value), the lod score method can
be applied to a sample of families where the segregation of the
disease and of a genetic marker is observed. It is then possible to
test whether the disease and the marker are transmitted indepen-
dently, that is, to test the recombination fraction between the
disease locus and the marker locus equal to 1/2, against the
linkage at u1 , 1⁄2, by comparing the likelihoods L(u 5 1⁄2) and L(u
5 u1). For a given family sample, the lod score for any candidate
recombination value u1 is defined as the decimal logarithm of the
ratio of the two likelihoods:
Z~u1! 5 log 10@L~u1!/L~u 5 1⁄2!#
For an autosomal disease, the hypothesis of linkage is accepted if
the lod score Z(u1) is greater than or equal to 3 and rejected for
u less than or equal to u1 if Z(u1) is smaller than or equal to 22.
The lod score computation is not restricted to a unique value u1,
but to a set of u values ranging from 0 to 1⁄2. To accept the
hypothesis of linkage, the critical value of 3 is then applied to the
maximum Zmax (u) of the lod function over the interval [0 to 1⁄2].
When a conclusion of linkage is reached, the estimate of the
recombination fraction is the value that maximizes the lod score
function.
Computation of a lod score requires the specification of an
underlying disease model that assigns the probabilities of geno-
types from the observed phenotypes. We studied the robustness
properties of the estimator of the recombination fraction u with a
monogenic model using the lod score method, when errors were
made in specifying the values of the disease locus parameters [2].
We showed that incorrect specifications, in particular the fre-
quency of the disease allele, may greatly bias the estimator of the
recombination fraction u. It may even lead to an exclusion of the
true location of a risk factor, as illustrated by the following
example: HLA typing was available for 58 nuclear families of
multiple sclerosis patients. As shown in Table 1, the presence of a
risk factor in the HLA region is excluded when applying the lod
score method, assuming a rare recessive allele (q 5 0.03) with a
penetrance of 0.43 (model proposed by Tiwari et al, [3]). In
contrast, evidence for a risk factor within the HLA region was
obtained when we assumed a frequent dominant allele (q 5 0.18)
with a low penetrance (f 5 0.02) [4].
In summary, this model based lod score method does not
provide a correct estimate of its parameter of interest (the
recombination fraction) when applied to a disease with an un-
known mode of inheritance.
The power of the linkage test depends on the strength of
evidence for various characteristics of the desired risk factor. In
particular, the power depends on the frequency of the risk factor
in both affected individuals and in normal people. It is clear that
the more ambiguous the relationship between phenotypes and
genotypes, the more difficult it is to obtain evidence for linkage. In
diseases involving many heterogeneous risk factors, each factor
taken alone has little influence on the disease status, so that this
ambiguity is at a maximum. It is therefore probable that the power
for detecting such a risk factor is a priori very low in those patients.
Mispecifying the underlying disease model will decrease this
power even more and may lead to a rejection of the entire genome
[5].
Other statistical methods for testing linkage have been pro-
posed that are model free include: (1) the sib-pair method
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proposed by Penrose (1935) and extended for the study of HLA
associated diseases [6–8]; repeat statistics [9]; extending studies to
affected relatives with a more distant relationship [10, 11]. Meth-
ods regressing the disease trait on the marker genotypes have also
been proposed [12, 13]. The principle of all these methods is to
test if relatives with the same status for the disease are more
similar for the marker than expected under independent segrega-
tion of the marker and the disease. For example, under indepen-
dent segregation of the disease and a marker, affected sibling-
pairs are expected to share 2, 1 and 0 alleles identical by descent
(IBD) in the proportion 1⁄4, 1⁄2, and 1⁄4, respectively. A deviation
from this expectation may be tested using a maximum likelihood
ratio MLS test as proposed by Risch [14, 15]. The MLS test is
sometimes referred to as a maximum logarithm of odds (lod
score). Note that the MLS test is also a parametric test, but is not
equivalent to the usual lod score test [1]. Indeed, the parameters
of interest are not the same; it is the IBD distribution on one hand
and the recombination fraction between the marker and disease
loci on the other. The statistical properties are, of course, also
different. Those of the MLS have been studied by Holmans [16].
The power to detect a linkage depends not only upon the
characteristics of the risk factor, but also upon the amount of
information in the marker. A highly polymorphic marker is
preferred. The information may be increased by using several
linked markers [17, 18].
The respective advantage of the different statistics used for
linkage test are still debated, but it is clear that their power all
depends on the genetic model underlying the disease trait. The
power to detect a risk factor involved in a multifactorial trait is
lower for a factor with a dominant effect than a recessive one, for
a high susceptibility allele frequency and a high phenocopy rate.
In addition, when some members of the family under examina-
tion are not typed, the statistic used for the linkage test depends
upon the frequency of the marker allele. Errors in these allele
frequencies may dramatically increase the rate of false positive
results. This problem may be crucial when applying the affected
sib-pair test to a late onset disease, since the parents are often
unavailable for typing (they have already died) [19]. This is also a
major problem in the affected pedigree member method where
unaffected members are systematically not typed [20] or in the
analysis of extended pedigrees where the first generations are
missing [21, 22].
The resolution of linkage analysis in the study of a multifacto-
rial disease is very limited. Indeed, linkage tests may indicate a
region where a disease risk factor is present, but the underdeter-
mination in this region will generally be large. Different parame-
ter values for the disease and the recombination fraction u
between a marker and disease locus may explain the same IBD
distribution in a sample of affected sibling-pairs. For example, in
a sample of type I diabetes sibling-pairs, the proportion sharing 2,
1 and 0 HLA haplotype(s) are 0.56, 0.38 and 0.06, respectively.
This IBD distribution may be equally explained either by a rare
recessive disease allele at a recombination fraction of 12% from
HLA or by a common recessive disease allele (q 5 0.35) within
HLA.
Recently, Hauser et al [23] proposed using the affected sibling-
pair information on two markers for a simultaneous estimation of
the IBD distribution and recombination fraction. However, first
they arbitrarily assumed that the risk factor locus was lying
between the two markers, and second they did not provide any
confidence interval for their estimates. In fact, the likely surface
for such a parametric study is very flat, as indicated by the study
of Kruglyak and Lander [17, 18], for which, even with a very dense
marker map, a fine resolution will not be obtained unless there is
a very large and unrealistic sample, particularly if each factor
involved in the disease has a weak effect by itself. Detecting
linkage with a genetic marker is a means of providing evidence for
the presence of a genetic risk factor in the marker region.
However, contrary to Mendelian diseases, a precise location of
the risk factor will not generally be obtained. It is only a first step
in a series of studies, and the establishment of a candidate gene
strategy seems to be an obligatory passage to identify the factors
involved in the disease process [24].
CANDIDATE GENE STRATEGY
A gene may be a candidate either because it is lying in a region
detected in a systematic screening or because it is functionally
related to the disease and thus may represent a risk factor. For
instance, genes of the HLA complex are currently candidates for
diseases with an immune component and apolipoprotein genes
are candidates for cardiovascular diseases. Thus, it is clear that the
question that must be addressed is not to localize a “disease gene”
but to obtain information concerning the role of a given “candi-
date gene” in the disease, and eventually to calculate the proba-
bility for an individual to develop the disease according to the
available information on this candidate gene.
The genotypes of the candidate gene are not always observable.
The information on a genetic marker situated at or near the
candidate gene locus can then be used. In addition to the
information provided by the marker at a familial level (correlation
between the disease status and the marker genotype in relatives),
the information may exist at a population level. This is the case if
there is gametic disequilibrium between a marker and a risk factor
for the disease in the considered population. In that situation, a
correlation may be observed between the disease status and the
marker genotypes in this population. This correlation is most
often evidenced by a comparison of the distribution of marker
genotypes between a sample of unrelated patients and a sample of
control individuals.
Most methods for the investigation of the role of a candidate
gene use only one type of information on the markers (either at
population or at family level), whereas they can be used together.
Simultaneously taking into account the information about both
the familial segregation and the population association of the
Table 1. Risk factor in HLA region
Recombination
fraction 0 between
HLA and MS disease
susceptibility locus
Recessive Dominant
q 5 0.03 f 5 0.43 q 5 0.18 f 5 0.02
0.00 231.34 3.11
0.01 219.83 3.06
0.02 214.08 3.00
0.03 210.32 2.94
0.04 27.59 2.897
0.05 25.51 2.80
0.06 23.87 2.72
0.07 22.56 2.64
0.08 21.49 2.56
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marker with the disease increases the power to show the involve-
ment of a candidate gene as a risk factor and also to model its role.
DETECTING A CANDIDATE GENE BY TESTING LINKAGE
AND ASSOCIATION
For a marker with two alleles, the transmission/disequilibrium
test (TDT) compares the alleles transmitted by heterozygous
parents to their affected child with the non-transmitted alleles,
and permits the simultaneous testing for linkage and association
[25]. Linkage can be detected by the TDT even in families with
only one affected member. It has been extended to the situation
of multi-allele marker loci [26, 27]. The alleles not transmitted to
the affected child create an internal family-based control group
that permits an estimation of relative risk [28–30]. A comprehen-
sive review of these methods may be found in a paper by Schaid
[31].
The power of the transmission disequilibrium test (TDT)
relative to that of the identity by descent (IBD) test depends upon
both the underlying genetic model and on the available family
data. When there is strong gametic disequilibrium, the TDT can
be more powerful than the IBD test [32]. This is well illustrated by
showing the role of insulin in indulin-dependent diabetes mellitus
(IDDM) [25] or the role of an HLA factor in multiple sclerosis
[33].
When there is gametic disequilibrium between the marker and
risk factor alleles, then the expectation of IBD sharing for an
affected sibling of an index patient depends upon the marker
genotype of this index [32]. Like the TDT, it is possible to
simultaneously test for linkage and association in testing the
homogeneity of the IBDkl distribution in sibling-pairs conditioned
on the genotype formed with marker allele k and marker allele l
of the index case (stratified IBD distribution). Note that with a
recessive disease model, homogeneity of the IBDkl distributions is
also expected. Consequently, gametic disequilibrium cannot be
detected in this situation.
MODELLING THE ROLE OF A CANDIDATE GENE
Two types of information (gametic disequilibrium and linkage)
can also be used to model the role of a risk factor.
The information provided by gametic disequilibrium between
the marker alleles and the risk factor alleles may be used through
the antigen genotype frequencies among patients (AGFAP)
method proposed by Thomson [34] and extended by Risch [35]. A
genetic model for the risk factor is tested by comparing the
marker genotype expected by using this model to the one ob-
served in a sample of unrelated patients. The information pro-
vided by the linkage between the marker and the risk factor locus
may be used through the IBD method proposed by Thomson and
Bodmer [7]. A genetic model for the risk factor is tested by
comparing the IBD distribution expected using this model to the
one observed in a sample of affected sibling-pairs.
If there is gametic disequilibrium, the power of model discrim-
ination may be increased by stratifying the affected sibling-pair
sample according to the index marker genotypes and using the
stratified IBD distribution.
THE MARKER ASSOCIATION SEGREGATION CHI-
SQUARE METHOD
The marker association segregation chi-square (MASC)
method is designed to model the role of the candidate gene in a
complex disease using both linkage and association information
[36]. The analysis is performed on nuclear families of index
patients. Index patients are classified into nested categories in
three steps according to: (1) the clinical status of their parents and
siblings (familial configuration); (2) their marker genotype; and
(3) their IBD status with a sibling.
The MASC method is a generalization of the AGFAP method
(corresponding to step 2) and of the stratified affected sib-pair
method (step 3). The index patients can be further categorized to
incorporate more information or to test more complex models,
such as the role of two candidate genes and their interactions [37].
The method is based on a comparison between the observed
categorized data and the expected data from various hypotheses,
particularly by using the hypothesis of no involvement of the
candidate gene.
The categories formed in each step are nested in the categories
of the previous step. Consequently, the outcomes are stochasti-
cally independent in each category of step 1, and are also
independent of the outcomes of the other steps. In addition to the
property of independence, the choice of the categories is made in
order to use the most relevant information. In the case of an
unspecified mode of ascertainment for the index cases, only steps
2 and 3 are used, but conditionally to the step 1 categories.
For a given genetic model, the expected number in each
category is computed conditionally on the observed number in the
category of the previous step. For each classification, the fit of the
genetic model to the observed data is tested by a X2 statistic.
Because of the independence of all these statistics, their sum Q
follows a X2 with the sum of the degrees of freedom of each
statistic [38]. The program MASC computes the expected values
in each category, then the Q value, and minimizes it in the
parameter space.
The MASC method has been applied to model the role of the
human leukocyte antigen (HLA) complex for different diseases of
the immune system such as insulin-dependent diabetes mellitus
(IDDM) [39], rheumatoid arthritis [37], multiple sclerosis [40]),
celiac disease [41]. The gain of information on the modelling of a
risk factor by using the MASC method is illustrated below on
IDDM data analysis.
ILLUSTRATION USING DATA ON INSULIN-DEPENDENT
DIABETES MELLITUS
Risk factor in the human leukocyte antigen region
In insulin-dependent diabetes mellitus (IDDM), an association
between some HLA antigens (in particular DR3 and DR4 in
Caucasian populations) and the disease has been shown. Distor-
tions in the segregation of the HLA markers in families with
affected individuals have also been reported, unambiguously
showing the existence of risk factor(s) in the HLA region.
In a sample of 158 Caucasian IDDM sibling-pairs, the propor-
tion of those sharing two, one or zero haplotypes are 0.56, 0.38
and 0.06, respectively. This IBD distribution nicely fits the effect
of a recessive risk factor allele with a frequency of 0.35. However,
such a model does not explain the AGFAP distribution at the DR
locus, in particular, the high proportion of heterozygotes
DR3DR4 compared to the proportion of homozygotes DR3DR3
or DR4DR4. Furthermore, it does not explain the difference in
the IBD distributions when stratified on the DR genotype index
cases. When the index cases are DR3DR4, the proportion of
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siblings sharing two HLA haplotypes is 71%, whereas it is only
46% when the index cases are DR4 non-DR3. It is obvious that
the contradiction in the model fitting is only due to the fact that
these approaches take into account different information, and
that to gain accuracy the maximum information must be used
simultaneously. We analyzed 416 HLA-typed, affected Caucasian
individuals and their relatives by the MASC method in order to
explain the entire observation [39].
We considered the classical models with one or two suscepti-
bility alleles at one locus, and because of its biological interest we
considered the possibility of a susceptibility molecule formed by
the complementation of two specific alleles at two loci in the HLA
region. Along this line of reasoning, Khalil et al [42] proposed a
susceptibility molecule composed of a DQa chain bearing an
arginine at position 52, Arg52(1), and a DQb chain lacking an
aspartic acid at position 57, asp57(2). This particular complemen-
tation model was also tested at the molecular level.
Using MASC, we demonstrated that among the models consid-
ered, only the complementation of two alleles at two distinct but
strictly linked loci was able to explain our data. In searching for
such an heterodimer, in view of our results, it appears that
molecular reseachers should not look for a sequence shared by
both DR3 and DR4 haplotypes. On the contrary, they should
focus on finding a combination of two sequences that differentiate
these haplotypes. In particular, we showed that the complemen-
tation of asp57(2) and arg52(1) cannot explain the HLA observa-
tions. MASC may provide an interactive link between the molec-
ular approach and the genetic modelling in the study of IDDM.
The HLA component of the genetic susceptibility to IDDM is
clearly complex.
Risk factor in the insulin region
Other familial factors, either genetic or environmental, are also
involved in IDDM. In particular, the role of a risk factor in the
insulin gene region has been clearly demonstrated. The demon-
stration of this risk factor provides a good illustration of how
information can be obtained from gametic disequilibrium.
Bell, Horita and Karam showed a strong association between
one allele (C1) of a 59 flanking polymorphism (59FP) of the insulin
gene and IDDM [43]. This result motivated an investigation of
this polymorphism in an affected IDDM sibling-pair sample
collected for a Genetic Analysis Workshop held in 1987. The IBD
distribution for the insulin region markers obtained on 95 IDDM
affected sibling-pairs (0.24, 0.52 and 0.24) did not show any
distortion when compared to that expected using independent
segregation of the insulin gene and IDDM. However, a clear
difference between the parental haplotypes transmitted and un-
stransmitted to the diabetic members was shown by several teams
[44, 45]. More recently, as an illustration of the TDT, Spielman,
McGinnis, and Ewens showed that, in this same family sample, the
57 parents heterozygous for the class 1 allele of 59FP transmitted
the class 1 allele to affected individuals 78 times, but did not
transmit it 46 times [25]. As demonstrated in the same article, this
strong difference permits the conclusion of simultaneous linkage
and gametic disequilibrium (P 5 0.004). This illustrates that in
some situations the TDT may be more powerful than IBD test for
detecting linkage.
The same evidence can be obtained from the IBD distribution
stratified on index genotypes for 59FP. It is interesting to note that
the proportion of siblings sharing two IBD insulin haplotypes with
the index cases is greater than 1/4 when the index is C1C1, but
lower than 1/4 in the other situations.
Table 2 illustrates the identity by descent (IBD) sharing distri-
bution for the insulin gene in the entire sample of affected
sibling-pairs in the subsample where the index is homozygous for
the C1 allele of 59FP and in the remaining sample of affected
sibling pairs (index different from C1C1).
Applying MASC to the observations on the insulin 59FP and
HLA indicates a simultaneous effect of risk factors in the HLA
and insulin regions [37]. A multiplicative effect of HLA and
insulin is not rejected, and the best fit model includes a comple-
mentation of susceptibility alleles in the HLA region and a
complete linkage disequilibrium between the insulin region risk
factor and the class 1 allele of 59FP. This model explains the
stratification observed in the IBD distribution for the insulin.
Note that when there is gametic disequilibrium, decreased IBD
sharing of affected sibling pairs in a subgroup may be observed.
The complete gametic disequilibrium between C1 and the insulin
risk factor is in favor of a direct implication of 59FP. This has been
also suggested by Bennet et al [46].
Risk factors for IDDM in other parts of the genome have been
recently shown by linkage analyses using a systematic screening
approach [47]. While the analysis revealed some regions of
interest on the genome, fine mapping of such regions is still a
difficult challenge with the current technology. Finding markers in
gametic disequilibrium with the risk factor would permit further
modelling of risk factors and unravelling of the genetic determi-
nants for IDDM.
The MASC method can be applied to the study of any complex
disease, provided there is information on polymorphic markers of
candidate genes. The greater the marker polymorphism and the
disequilibrium between marker alleles and the candidate gene
alleles, the better the information on the potential role of the
candidate gene. The advantage of the MASC method is to
potentiate the information provided by linkage and gametic
disequilibrium.
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